16 / 25
PCOS 2018
Journal of Clinical and Molecular Endocrinology
ISSN: 2572-5432
Page 44
June 07-08, 2018
London, UK
4
th
World Congress on
Polycystic Ovarian
Syndrome
P
olycystic ovary syndrome (PCOS) is a complex syndrome
characterized by reproductive and metabolic implications.
Pharmacologic treatments target the hormonal and metabolic
dysregulations associated to the disease such as insulin
resistance, anovulation, hirsutism and menstrual irregularities.
Inositol consists of nine stereoisomeric forms, all having a
ring made by six carbons with a hydroxyl group attached to
each carbon. Such stereoisomers are engendered through the
epimerization of the hydroxy groups. Myo-inositol (MI) is themost
important and widespread inositol. Also, D-chiro-inositol (DCI)
deserves great attention; it is originated from MI by means of
the epimerization of the C1 hydroxyl group, furthermore it exists
at a 40:1 ratio between myo-inositol and D-chiro-inositol. This
enzymatic reaction is controlled by insulin and acts in agreement
with specific tissue necessities. MI in the ovary is involved in
glucose uptake and FSH signalling while DCI works as inducer
of testosterone synthesis under insulin stimulus. In insulin
resistant PCOS women, hyperinsulinemia ends causing a severe
growth of DCI concentrations from MI thorough the upregulation
of epimerase activity in the ovary. MI could play a pivotal role in
re-addressing both hormonal and metabolic parameters toward
homeostasis, counteracting the symptoms and signs typical of
this syndrome. In fact, our personal data showed an improvement
of menstrual disorder, hirsutism and both a reduced ovarian
hyperandrogenism and hyperinsulinism by six months of a
combined treatment with MI+DCI. MI and DCI could represent an
alternative important new tool for the management of metabolic
and hormonal features inPOCS, although longitudinal randomised
studies alongwith prospective interventional trialsmay contribute
to better clarify the role of this intriguing and safe new therapy.
francescoorio@virgilio.itInositol: A new pharmacological tool for several issues in PCOS
Francesco Orio
University of Naples Federico II, Italy
J Clin Mol Endocrinol 2018, Volume 3
DOI: 10.21767/2572-5432-C1-003